Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults

17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick

24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...

Read more →

Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis

25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...

Read more →

New Brunswick becomes third province in Canada to implement biosimilar switching policy

21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...

Read more →

Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer

15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...

Read more →